VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).
H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in Japan.
The ODD in Japan adds to other important designations: the SAKIGAKE designation by Japan's MHLW in March 2023, the Orphan Drug Designation (ODD) by the US FDA in April 2024, and by EMA in May 2021.
"We are pleased to receive Orphan Drug Designation for amlenetug in Japan. This designation highlights the potential of amlenetug as a treatment option for people living with Multiple System Atrophy. We are hopeful of the potential for amlenetug to slow the clinical progression of this devastating disease and look forward to advancing its development through the MASCOT trial", said Johan Luthman, EVP and Head of Research & Development at Lundbeck.
Lundbeck has recently initiated, MASCOT, a phase III trial to assess efficacy and safety of amlenetug in the treatment of MSA.
The MASCOT trial will open for enrollment in North America, Europe, Asia and Australia.
About Amlenetug
Amlenetug is a human monoclonal antibody (mAb) that recognizes and binds to all major forms of extracellular a-synuclein and thereby intended to prevent uptake and inhibit seeding of aggregation. Amlenetug has an active Fc region, which may increase immune-mediated clearance of a- synuclein /mAb complexes through microglia mediated uptake.
Amlenetug is being developed by Lundbeck under a joint research and licensing agreement between Lundbeck and Genmab A/S.
About the MASCOT trial
MASCOT (NCT06706622) is a phase III, interventional, randomized, double-blind, parallel-group, placebo-controlled, optional open-label extension trial that will be conducted in North America, Europe, and Asia.
The trial comprises 2 parts: A double-blind period where participants are randomized to receive either high or low doses of amlenetug, or placebo for 72 weeks, followed by an open-label extension period where all participants enrolled in the trial are offered treatment with amlenetug
The aim of the trial is to evaluate the efficacy, safety, and tolerability of amlenetug in patients with MSA. Amlenetug will be delivered as an intravenous infusion every four weeks.
About MSA
MSA is a rapidly progressing rare condition of the nervous system that causes damage to nerve cells in the brain. MSA is seriously debilitating and places a high disease burden on patients. Symptoms of MSA usually start between 55 and 60 years of age and the patients typically live for 6 to 9 years after symptom onset.
In people living with MSA, an abnormal build-up of the protein alpha-synuclein is thought to be responsible for damaging areas of the brain that control balance, movement, and the body's normal functions. The symptoms of MSA are wide-ranging and include muscle control problems, similar to those of Parkinson's disease. Many different functions of the body can be affected, and symptoms including urinary incontinence, frequent falling, and unintelligible speech occur within 3 years of disease onset and are accompanied by reduced capacity to live independently. Death is often due to respiratory problems. Although there are many different possible symptoms of MSA, not everyone who is affected will experience all of them. There is currently no cure for MSA and no available treatment to slow its progression.
References
NHS: Multiple system atrophy - NHS (www.nhs.uk)
Contacts
Thomas Mikkel Mortensen | Jens Høyer | ||
Media Relations Lead, Corp. Communication | Vice President, Head of Investor Relations | ||
THMR@lundbeck.com | JSHR@lundbeck.com | ||
+45 30 83 30 24 | +45 30 83 45 01 | ||
Palle Holm Olesen | |||
Vice President, Investor Relations | |||
PALO@lundbeck.com | |||
+45 30 83 24 26 |
About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.
Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.
We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.
Lundbeck has approximately 5,500 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.
CONTACT:
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311
info@lundbeck.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/h--lundbeck-a-s/r/lundbeck-s-potential-treatment-for-multiple-system-atrophy-granted-orphan-drug-designation-in-japan,c4116334
The following files are available for download:
https://mb.cision.com/Main/18215/4116334/3308944.pdf | Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan |
View original content:https://www.prnewswire.co.uk/news-releases/lundbecks-potential-treatment-for-multiple-system-atrophy-granted-orphan-drug-designation-in-japan-302396851.html
